First half of 2025 saw progress toward commercialization with a paid feasibility study, a granted European patent, and a successful share issue. Financials reflect ongoing development with negative results but strong liquidity and high equity ratio.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.